A rare disease advocacy coalition on Wednesday urged the ‌Trump administration to restore regulatory clarity as it considers ...

Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill ...

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity ...

The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a ...

PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of ...

The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss.

April 1 (Reuters) - The U.S. Food and Drug Administration on Wednesday clarified its policies on compounded versions of ...

The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold ...

The daily pill, called Foundayo, is the second oral GLP-1 product to reach the market over the past few months.

A new daily pill, called Foundayo, is the second oral GLP-1 to reach the market in recent months, following the FDA approval ...

Food ‌and Drug Administration ​is moving toward allowing compounding pharmacies ‌to ⁠produce more than ⁠a dozen injectable ...